Kasahara Ryo, Nakaigawa Noboru, Kobayashi Kazuki
Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
Department of Urology, Yokohama City University Hospital, Yokohama, Japan.
Case Rep Oncol Med. 2017;2017:2648471. doi: 10.1155/2017/2648471. Epub 2017 Sep 20.
A 79-year-old Japanese man underwent a medical examination for hoarseness. Computed tomography revealed a left renal tumor, and radical nephrectomy was performed. The tumor was a clear cell carcinoma. Fourteen months after the operation, the tumor had metastasized to the spleen, right lung, and retroperitoneal lymph nodes. We initiated molecular targeted therapy sequentially with sorafenib, sunitinib, and axitinib and then conducted a rechallenge with sorafenib. His metastatic lesions had completely vanished 5 months after initiation of the rechallenge. Ten months after the rechallenge, lumbar vertebral body metastasis appeared. However, we consider that the sorafenib rechallenge was effective because of the very slow growth of the metastatic lesion, with no other metastasis for 30 months, at the time of writing this report. Approximately 7 years after the first local recurrence, he remained alive, with relatively normal daily functioning.
一名79岁的日本男性因声音嘶哑接受了医学检查。计算机断层扫描显示左肾肿瘤，遂进行了根治性肾切除术。肿瘤为透明细胞癌。术后14个月，肿瘤转移至脾脏、右肺和腹膜后淋巴结。我们先后依次使用索拉非尼、舒尼替尼和阿昔替尼进行分子靶向治疗，然后再次使用索拉非尼进行挑战治疗。再次挑战治疗开始5个月后，他的转移病灶完全消失。再次挑战治疗10个月后，出现了腰椎椎体转移。然而，我们认为再次使用索拉非尼进行挑战治疗是有效的，因为转移病灶生长非常缓慢，在撰写本报告时，30个月内没有出现其他转移情况。首次局部复发约7年后，他仍然存活，日常功能相对正常。
